The Oncotype MAPTM
Pan-Cancer Tissue test may help inform treatment options for those individuals facing the challenges of advanced-stage cancer. Receiving comprehensive information quickly to inform treatment decisions could be life-changing.
The Oncotype MAP Pan-Cancer Tissue test is most appropriate for patients with:
- Advanced cancer: A cancer that is unlikely to be cured or controlled with treatment. This type of cancer may have spread from its primary site to nearby tissue, lymph nodes or distant parts of the body.
- Metastatic cancer: A cancer that has spread from its primary site to other places in the body.
- Refractory (resistant) cancer: A cancer that does not respond to treatment. Refractory cancer may be resistant at the beginning of treatment or become resistant during a course of treatment.
- Recurrent cancer: A cancer that has recurred or come back, usually after a period of time during which the cancer could not be detected. Recurrent cancers may come back to the same place as the original (primary) tumor or to another place in the body.
- Relapsed cancer: A cancer that has returned after a period of improvement, usually after treatment.
The test can also provide valuable data and analysis to inform treatment decisions when no standard of care exists or the tumor is particularly aggressive or invasive.
Insurance Coverage and Financial Assistance
The Oncotype MAP Pan-Cancer Tissue Test is covered by Medicare
and private insurers for eligible patients, while Exact Sciences’ Genomic Access Program (GAP) helps patients navigate insurance and other payment options for Oncotype tests.